Publications

Find at Harvard

Read Now

November 2012
Supplement

Amylin Pharmaceuticals (B)

By: Richard G. Hamermesh and Carin-Isabel Knoop

Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details

Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States

2024
Working Paper

Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances

By: Amar Bhidé and Srikant M. Datar

In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the... View Details

Keywords: Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms

SSRN

Read Now

January 2021
Case

mPharma (A)

By: Rembrand Koning, John D. Macomber, Pippa Tubman Armerding and Wale Lawal

mPharma pioneered electronic prescriptions in Ghana, and aimed to increase drug affordability and accessibility in Africa, but the company remained unprofitable. Following investor concerns about mPharma's business, CEO Gregory Rockson considered alternative business... View Details

Keywords: Strategy; Entrepreneurship; Acquisition; Health; Business Model; Health Industry; Technology Industry; Ghana

October 2012
Supplement

Aqua Bounty Courseware

By: Lucy White and Steve Burn-Murdoch

Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details

Keywords: IPO; Valuation; Real Options; Decision Tree; Biotech; Genetically Modified; Salmon; Entrepreneurship; Finance; Agriculture and Agribusiness Industry; Biotechnology Industry; North and Central America; Europe; South America

February 2002 (Revised August 2002)
Case

Inhale Therapeutics: Executing and Growing the Business Model

Inhale is about to bring a novel technology to market that uses inhalation to administer drugs that formerly required injection. Inhale must now decide which way to evolve its business model. This will determine the future direction of growth for the company. View Details

Keywords: Business Model; Technological Innovation; Health Care and Treatment; Growth and Development Strategy; Medical Devices and Supplies Industry

Find at Harvard

September 1993
Supplement

Manufacturing at ALZA: The Right Prescription? (C)

By: Dorothy A. Leonard

ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details

Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry

Find at Harvard

28 Sep 2020
Working Paper Summaries

What Can Economics Say About Alzheimer's Disease?

Keywords: by Amitabh Chandra, Courtney Coile, and Corina Mommaerts; Health; Pharmaceutical

12 Jul 2016
First Look

July 12, 2016

of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic (large-molecule) drugs represent a disproportionate and growing share of all drug spending in... View Details

Keywords: Sean Silverthorne

Research Summary

Overview

By: John Beshears

In his research, Professor Beshears shows how managers can influence the behavior of customers and employees by changing the decision-making environment to call attention to a decision, to use psychological framing to shape assessments of options, or to help... View Details

Keywords: Behavioral Economics; Consumer Finance; Household Finance; Health Care; Organizational Economics; Decision Making; Economics; Negotiation; Behavioral Finance

May 2002 (Revised October 2005)
Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman

Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details

Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States

January 2001
Case

Merck Global Health Initiatives (B): Botswana

By: James E. Austin, Diana Barrett and James Weber

The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details

Keywords: Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Africa; Botswana

January 2014 (Revised June 2014)
Case

23andMe: Genetic Testing for Consumers (A)

By: John A. Quelch and Margaret L. Rodriguez

On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was... View Details

Keywords: Public Health; Genome Testing; Health Care; Ancestry; 23andMe; Marketing; Product Launch; Health; Health Care and Treatment; Health Testing and Trials; Genetics; Strategy; Health Industry; United States

01 Oct 2018
Working Paper Summaries

Negative Shocks and Innovation: Evidence from Medical Device Recalls

Keywords: by George P. Ball, Jeffrey T. Macher, and Ariel Dora Stern; Health; Medical Devices & Supplies

March 1999 (Revised June 2000)
Case

Eli Lilly: The Evista Project

By: Steven C. Wheelwright and Matt Verlinden

Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)... View Details

Keywords: Projects; Groups and Teams; Operations; Management Teams; Product Development; Transition; Product Design; Business Startups; Business Plan; Product Launch; Competition; Service Operations; Pharmaceutical Industry

24 Sep 2007
Research & Ideas

The FDA: What Will the Next 100 Years Bring?

The U.S. Food and Drug Administration, which was created by the passage of the 1906 Federal Food and Drugs Act, regulates companies and industries accounting for one-quarter of all consumer spending, roughly... View Details

Keywords: by Sean Silverthorne; Biotechnology; Consumer Products; Food & Beverage; Health

February 2024
Case

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu

This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details

Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom

October 2007 (Revised July 2013)
Case

Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech

By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan

In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details

Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Biotechnology Industry; Pharmaceutical Industry; San Diego

January 1999
Background Note

Note on the Drugstore Industry

By: David E. Bell and Ann Leamon

In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details

Keywords: History; Industry Growth; Retail Industry; Pharmaceutical Industry